Moonwalk Biosciences closed a $70 million Series B to advance MW-101, an adipose-targeted RNAi obesity candidate, into human testing. The company plans late-2027 first-in-human studies after completing IND-enabling work, with proceeds also supporting additional tissue-targeted siRNA programs.